Prognostic Factors for Survival Outcome of High-Grade Multicentric Glioma

Wang, Tianwei; Niu, Xiaodong; Gao, Ting; Zhao, Lingling; Li, Jiaoming; Gan, Youjun; Liu, Qing; Mao, Qing

doi:10.1016/j.wneu.2018.01.035

Cited by 17 publications

(20 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Increasing evidence has indicated that the traditional classification of glioma provides very little insight into the biological behavior and molecular mechanisms that could be used as therapeutic targets. Therefore, the identification of new prognostic biomarkers is urgently needed to evaluate the malignancy and long‐term outcome of glioma …”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Combined elevation of TRIB2 and MAP3K1 indicates poor prognosis and chemoresistance to temozolomide in glioblastoma

et al. 2019

View full text Add to dashboard Cite

Introduction Glioblastoma (GBM) is the most lethal primary malignant brain tumor in adults with poor survival due to acquired therapeutic resistance and rapid recurrence. Currently, the standard clinical strategy for glioma includes maximum surgical resection, radiotherapy, and temozolomide (TMZ) chemotherapy; however, the median survival of patients with GBM remains poor despite these comprehensive therapies. Therefore, the identification of new prognostic biomarkers is urgently needed to evaluate the malignancy and long‐term outcome of glioma. Aims To further investigate prognostic biomarkers and potential therapeutic targets for GBM. Results In this study, we identified tribbles pseudokinase 2 (TRIB2) as one of the genes that is most correlated with pathological classification, radioresistance, and TMZ resistance in glioma. Additionally, the expression of mitogen‐activated protein kinase kinase kinase 1 (MAP3K1) showed a strong correlation with TRIB2. Moreover, a combined increase in TRIB2 and MAP3K1 was observed in GBM and indicated a poor prognosis of patients with glioma. Finally, enriched TRIB2 expression and MAP3K1 expression were shown to be associated with resistance to TMZ and radiotherapy. Conclusion Combined elevation of TRIB2 and MAP3K1 could be novel prognostic biomarkers and potential therapeutic targets to evaluate the malignancy and long‐term outcomes of GBM.

show abstract

Section: Introductionmentioning

confidence: 99%

“…Therefore, the identification of new prognostic biomarkers is urgently needed to evaluate the malignancy and longterm outcome of glioma. 3,4 Tribbles pseudokinase 2 (TRIB2) is a kinase-encoding gene of the tribbles family. TRIB2 was first identified to regulate mitosis and embryonic development in Drosophila.…”

mentioning

confidence: 99%

Combined elevation of TRIB2 and MAP3K1 indicates poor prognosis and chemoresistance to temozolomide in glioblastoma

et al. 2019

View full text Add to dashboard Cite

show abstract

“…This comprehensive analysis of multicentric glioma patients revealed that age > 54 years old, surgical resection, and radiotherapy were significantly associated with improved survival and were independent prognostic factors for OS. Radiotherapy and radiotherapy combined with chemotherapy were independent prognostic factors for surgical patients' OS as well [37]. There are many reasons for conflicting results, such as differences in sample size, ethnicity, tumor grade, and experiment method.…”

Section: Discussionmentioning

confidence: 99%

Role of PVT1 Polymorphisms in the Glioma Susceptibility and Prognosis

Ding

Zhao

Yuan

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Genetic factors play a crucial role in the glioma risk and prognosis of glioma patients. To explore the role of PVT1 polymorphism in the susceptibility and survival of glioma in the Chinese Han population, we conducted a case-control study.Methods: The three single-nucleotide polymorphisms (SNPs) in PVT1 were genotyped using Agena MassARRAY from 575 patients with glioma and 500 healthy controls. We used the χ 2 test to analyze the differences in distribution of allele and genotype between the cases and controls. Odds ratio (OR) and 95% confidence interval (95% CI) were calculated by logistic regression analysis to evaluate the association SNPs with glioma risk. The effects of polymorphisms and clinical features on survival of glioma patients were evaluated using the log-rank test, Kaplan-Meier and Cox regression analysis.Results: We found that rs13255292 was associated with a decreased risk of glioma in the recessive model in overall or male; and rs4410871 was significantly associated with an increased the risk of glioma in age≤40 years old or female. Moreover, the extent of resection and chemotherapy were found to be key prognostic factors in survival of glioma patients. However, the gender, age, tumor grade, radiotherapy and PVT1 polymorphisms have no effect on prognosis of glioma patients.Conclusions: Our results indicated that PVT1 polymorphisms (rs13255292 and rs4410871) were associated with glioma susceptibility, but have no effect on prognosis of glioma patients. Further studies with large samples are required to confirm the results.

show abstract

“…This fact might seem inconsistent with the accepted statement of EoR being a major prognostic factor, it is clear that is not the only one. Probably, other prognostic factors such as the histological subtype, molecular biology or availability of therapeutic targets, and adjuvant therapies might play a more significant role (29)(30)(31)(32)(33)(34).…”

Section: Discussionmentioning

confidence: 99%

Cost-Effectiveness of Low-Field Intraoperative Magnetic Resonance in Glioma Surgery

et al. 2020

View full text Add to dashboard Cite

Low-field intraoperative magnetic resonance (LF-iMR) has demonstrated a slight increase in the extent of resection of intra-axial tumors while preserving patient`s neurological outcomes. However, whether this improvement is cost-effective or not is still matter of controversy. In this clinical investigation we sought to evaluate the costeffectiveness of the implementation of a LF-iMR in glioma surgery. Methods: Patients undergoing LF-iMR guided glioma surgery with gross total resection (GTR) intention were prospectively collected and compared to an historical cohort operated without this technology. Socio-demographic and clinical variables (pre and postoperative KPS; histopathological classification; Extent of resection; postoperative complications; need of re-intervention within the first year and 1-year postoperative survival) were collected and analyzed. Effectiveness variables were assessed in both groups: Postoperative Karnofsky performance status scale (pKPS); overall survival (OS); Progression-free survival (PFS); and a variable accounting for the number of patients with a greater than subtotal resection and same or higher postoperative KPS (R-KPS). All preoperative, procedural and postoperative costs linked to the treatment were considered for the cost-effectiveness analysis (diagnostic procedures, prosthesis, operating time, hospitalization, consumables, LF-iMR device, etc). Deterministic and probabilistic simulations were conducted to evaluate the consistency of our analysis. Results: 50 patients were operated with LF-iMR assistance, while 146 belonged to the control group. GTR rate, pKPS, R-KPS, PFS, and 1-year OS were respectively 13,8% (not significative), 7 points (p < 0.05), 17% (p < 0.05), 38 days (p < 0.05), and 3.7% (not significative) higher in the intervention group. Cost-effectiveness analysis showed a mean incremental cost per patient of 789 € in the intervention group. Incremental costeffectiveness ratios were 111 € per additional point of pKPS, 21 € per additional day free of progression, and 46 € per additional percentage point of R-KPS. Conclusion: Glioma patients operated under LF-iMR guidance experience a better functional outcome, higher resection rates, less complications, better PFS rates but

show abstract

Prognostic Factors for Survival Outcome of High-Grade Multicentric Glioma

Cited by 17 publications

References 26 publications

Combined elevation of TRIB2 and MAP3K1 indicates poor prognosis and chemoresistance to temozolomide in glioblastoma

Combined elevation of TRIB2 and MAP3K1 indicates poor prognosis and chemoresistance to temozolomide in glioblastoma

Role of PVT1 Polymorphisms in the Glioma Susceptibility and Prognosis

Cost-Effectiveness of Low-Field Intraoperative Magnetic Resonance in Glioma Surgery

Contact Info

Product

Resources

About